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Abstract
Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower administered
dosage for the treatment of erectile dysfunction. However, the molecular basis for these differences
is puzzling because two drugs have similar chemical structures. Reported here is a crystal structure
of the fully active and nonmutated PDE5A1 catalytic domain in complex with vardenafil. The
structure shows that the conformation of the H-loop in the PDE5A1-vardenafil complex is different
from those of any known structures of the unliganded PDE5 and its complexes with the inhibitors.
In addition, the molecular configuration of vardenafil differs from that of sildenafil when bound to
PDE5. It is noteworthy that the binding of vardenafil causes loss of the divalent metal ions that have
been observed in all the previously published PDE structures. The conformational variation of both
PDE5 and the inhibitors provides structural insight into the different potencies of the drugs.
Cyclic nucleotide phosphodiesterases (PDEs) are key enzymes controlling cellular
concentrations of the second messengers cAMP and cGMP (Mehats et al., 2002; Houslay and
Adams, 2003; Goraya and Cooper, 2005; Bender and Beavo, 2006; Lugnier, 2006; Conti and
Beavo, 2007; Omori and Kotera, 2007). The human genome encodes 21 PDE genes that are
categorized into 11 families. Alternative mRNA splicing of the PDE genes produces
approximately 100 iso-forms of PDE proteins that distribute in various cellular compartments
and control myriad physiological processes. PDE molecules contain a variable regulatory
domain and a conserved catalytic domain but show distinct substrate specificity and inhibitor
selectivity. Family-selective PDE inhibitors have been widely studied as therapeutic agents for
treatment of various human diseases, including cardiotonics, vasodilators, smooth muscle
relaxants, antidepressants, antithrombotics, antiasthmatics, and agents for improving learning
and memory (Truss et al., 2001; Rotella, 2002; Schrör, 2002; Castro et al., 2005; Houslay et
al., 2005; Lipworth, 2005; Blokland et al., 2006; Menniti et al., 2006).
The most successful examples of this class of drugs are the PDE5 inhibitors (Fig. 1) sildenafil
(Viagra), vardenafil (Levitra), and tadalafil (Cialis), which have been used for treatment of
male erectile dysfunction (Rotella et al., 2002). Sildenafil (Revatio) has also been approved
for treatment of pulmonary hypertension (Galié et al., 2005). Korean authorities have recently
approved udenafil (Fig. 1) for treatment of male erectile dysfunction (Salem et al., 2006) .
Although these four PDE5 inhibitors have been successfully approved as the drugs for
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treatment of human diseases, the enthusiasm for development of novel PDE5 inhibitors
continues. PDE5 inhibitors have been shown to have potential for other medical applications,
including improvement of memory and treatment of cancer and heart disease (Blokland et al.,
2006;Salem et al., 2006;Stehlik and Movsesian, 2006;Supuran et al., 2006;Padma-Nathan et
al., 2007;Palmer et al., 2007;Zhu and Strada, 2007;Sandner et al., 2008). Much attention has
been focused on the recent development of the second generation of PDE5 inhibitors that have
the same or different scaffolds from the current drugs but different pharmaco-kinetic profiles
(Palmer et al., 2007).
Sildenafil, vardenafil, and udenafil have similar chemical formulae (Fig. 1) and possess similar
key pharmacophores that provide for their function. These inhibitors also have the same target
and interact with many of the same residues at the active site of PDE5, as shown by the crystal
structures of the isolated PDE5 catalytic domain in complex with sildenafil and vardenafil
(Sung et al., 2003;Card et al., 2004;Huai et al., 2004;Zhang et al., 2004;Wang et al., 2006).
Although the head-to-head comparison is still lacking, the pharmaco-kinetic and
pharmacodynamic analyses showed that these PDE5 inhibitors have similar efficacy and
tolerance but exhibit some functional differences both in vitro and in vivo (Briganti et al.,
2005;Shabsigh et al., 2006;Supuran et al., 2006;Wright, 2006;Doggrell, 2007;Mehrotra et al.,
2007). For example, vardenafil shows 10- to 40-fold tighter binding with PDE5 than sildenafil
and has an area under the curve of 74.5 μg · h/liter at a 20-mg dosage compared with 1965 for
sildenafil at a 100-mg dosage (Shabsigh et al., 2006;Mehrotra et al., 2007).
However, the structural basis for the different potencies of these inhibitors is still puzzling.
The early studies on the crystal structures of PDE5 in complex with sildenafil and vardenafil
by two groups showed inconsistent results. Vardenafil and sildenafil have the same extended
configuration in the crystal structures reported by Sung et al. (2003), in contrast to the folded
configuration of both inhibitors in the report by Zhang et al. (2004). Because the PDE5A
catalytic domain used by Sung et al. (2003) is basically inactive and the structure reported by
Zhang et al. (2004) contains a chimeric replacement of the PDE5A H-loop with the PDE4D
H-loop, the biologically relevant conformation of these drugs has remained a question.
To address this question, the crystal structure of the fully active and nonmutated catalytic
domain of PDE5A1 in complex with vardenafil has been determined and compared with the
previously published cocrystal structures of the enzyme with sildenafil and vardenafil. The
structural comparison shows dramatic differences between the vardenafil and sildenafil
complexes in both PDE5 protein conformation and the inhibitor configuration. These
differences are likely to contribute to the different properties of these drugs.
Materials and Methods
Protein Expression and Purification of the PDE5A1 Catalytic Domain
The cDNA of the catalytic domain of human PDE5A1 was generated by site-directed
mutagenesis of the gene of bovine PDE5A, as described previously (Wang et al., 2006). The
coding region for amino acids 535 to 860 of PDE5A1 was amplified by PCR and subcloned
into the expression vector pET15b. The resultant plasmid pET-PDE5A1 was transferred into
Escherichia coli strain BL21-CodonPlus (Stratagene, La Jolla, CA) for overexpression. The
E. coli cell carrying pET-PDE5A1 was grown in Luria-Bertani medium at 37°C to absorption
A600 = 0.7 and then 0.1 mM isopropyl β-D-thiogalactopyranoside was added for further growth
at 15°C overnight. Recombinant PDE5A1 was passed through the nickelnitrilotriacetic acid
affinity column (QIAGEN, Valencia, CA), subjected to thrombin cleavage to remove the His
tag, and further purified by Q-Sepharose and Sephacryl S300 column chromatography (GE
Healthcare, Chalfont St. Giles, Buckinghamshire, UK). A typical purification yielded over 10
mg of PDE5A1 with a purity >95% from a 2-liter cell culture.
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Protein Crystallization and Structure Determination
The cocrystal of PDE5A1 (535–860) with vardenafil was grown by vapor diffusion. The
complex of PDE5A1-vardenafil was prepared by mixing 1 mM vardenafil with 15 mg/ml
PDE5A1 at 4°C overnight. The protein drop was set up by mixing 2 μl of protein solution with
2 μl of well buffer and crystallized against a well buffer of 12% polyethylene glycol 3350, 15%
glycerol, and 0.1 M sodium acetate pH 4.6 at 25°C. The PDE5A1-vardenafil crystals have the
space group P212121 with cell dimensions of a = 68.9, b = 87.8, and c = 138.5 Å (Table 1).
Diffraction data were collected on beamline X29 at Brookhaven National Laboratory and
processed by program HKL (Otwinowski and Minor, 1997).
The structure of the PDE5A1-vardenafil cocrystal was solved by molecular replacement
program AMoRe (Navaza and Saludjian, 1997), using the PDE5A1-IBMX structure without
the H-loop as the initial model. The atomic model was built with the use of the program O
(Jones et al., 1991) against the electron density map that was improved by the density
modification package of CCP4. The structure was refined by CNS (Crystallography and NMR
System) (Table 1; Brünger et al., 1998). The atomic coordinates and structural factors have
been deposited into the Protein Data Bank with accession code 3B2R.
Results
Architecture of the PDE5-Vardenafil Structure
The enzyme of the PDE5A1 catalytic domain used in these studies was fully active and
exhibited kinetic properties (kcat, Km) similar to those for the full-length PDE5A1 (Wang et
al., 2006). The structure of the PDE5A1 catalytic domain (residues 535–860) in complex with
vardenafil consists of 15 α-helices (Fig. 2). Most of the residues in the PDE5A1-vardenafil
cocrystal had solid electron density and were traced without ambiguity. Residues 660 to 672
and 792 to 806, which are parts of the H- and M-loops, lacked electron density and were
disordered. The superimposition of PDE5A1-vardenafil over other previously determined
PDE5A1 structures (Huai et al., 2004; Wang et al., 2006) yielded root-mean-square deviations
of 0.49, 0.54, 0.51, and 0.47 Å, respectively for Cα atoms of 270 comparable residues (536–
657, 686–787, and 813–859) of the unliganded PDE5A1 and its complexes with IBMX, icarisid
II, and sildenafil, indicating the overall similarity among the PDE5 structures. However, the
PDE5A1-vardenafil structure shows dramatic conformation differences in the H-and M-loops
from the known PDE5 structures.
Different Conformational Changes Induced by Vardenafil and Sildenafil Binding
The H-loop of PDE5 was previously shown to have four different conformations depending
on the liganded state of the protein: 1) a coil conformation in the unliganded state, 2) two short
α-helices (H8 and H9) at residues 664 to 667 and 672 to 676 in the IBMX complex, 3) a 310
helix in the sildenafil complex, and 4) two short β-strands in the icarisid II complex (Wang et
al., 2006). In addition, these conformation changes of the H-loop upon the inhibitor binding
are coupled with the dramatic positional movements, up to 7, 24, and 35 Å in these three
complexes, respectively. The position and conformation of the H-loop in the PDE5A1-
vardenafil structure also differs significantly from those of the known PDE5 structures. First,
helix H9 in the PDE5A1-vardenafil cocrystal contains residues Ser675 to Ile680, compared
with the sequence of 671 to 675 in the PDE5A1-IBMX complex; the latter composition of the
H-loop resembles the residues of helix H9 in other PDE families (Ke and Wang, 2007). Second,
the H-loop in the PDE5A1-vardenafil complex shows a positional shift of as much as 20 Å
from that in the unliganded form. Third, the N-terminal residues 680 to 685 of helix H10 that
contains residues 680 to 693 in all the early structures of PDE5 and other PDE families are in
a coil conformation in the PDE5A1-vardenafil structure. Finally, residues 792 to 808 of the
M-loop in the PDE5A1-vardenafil structure are disordered. This disorder is similar to features
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of this region found in the unliganded and IBMX-bound PDE5A1 structures (Wang et al.,
2006) but is in contrast to the ordered conformation of the M-loop in the cocrystal structures
of PDE5-sildenafil and PDE5-icarisid II. Because the M-loop contains a coiled fragment
around Leu804 that contacts the inhibitors and most likely the cGMP substrate (Fig. 2), its
disorder in the PDE5A1-vardenafil structure is likely to have some implication for both
inhibitor and substrate binding. However, this possibility will require further study.
Vardenafil Caused Loss of the Divalent Metal Binding
The most surprising feature of the PDE5A1-vardenafil structure is the absence of divalent
metals at the active site (Fig. 2). This is in contrast to the absolute conservation of the binding
of two divalent metal ions at the active sites of all early reported structures of PDE5 and other
PDE families (Wang et al., 2006;Ke and Wang, 2007), even in the presence of the metal-
chelating agent EDTA during the protein purification of the PDE4B2B catalytic domain (Xu
et al., 2000). Because the divalent metals and their binding residues are not involved in
crystallographic lattice contacts, the loss of the divalent metals in the PDE5-vardenafil complex
is unlikely to be an artifact of the crystal packing. Rather, the loss of the metal ions in the PDE5-
vardenafil structure is apparently due to the influence of the conformational changes in the H-
loop. A careful examination shows that two of the zinc-binding residues (His617 and Asp764)
are well superimposed with those in the other PDE5 structures (Fig. 2D), as shown by small
positional differences of 0.15 and 0.19 Å for their Cα atoms between the structures of PDE5A1-
vardenafil and PDE5A1-sildenafil. However, two other important metal-binding residues
(His653 and Asp654) in the PDE5A1-vardenafil complex show shifts of 0.76 and 0.80 Å from
those in the PDE5A1-sildenafil complex although their conformations are retained; the
magnitudes of these shifts are almost twice the overall root-mean-square deviation of 0.47 Å
for all the atoms in the structures. In addition, the positioning of His684 in the PDE5-vardenafil
complex is completely different from that in the PDE5-sildenafil structure, and its imidazole
ring is now located at the site normally occupied by the second metal ion or magnesium (Fig.
2D). Thus, the positional and conformational changes of Asp654 and His684 apparently act to
eliminate binding of both divalent cations. Because Asp654 and His684 are located,
respectively, at the N and C termini of the H-loop, the conformational change of the H-loop
upon vardenafil binding seems to be the driving force that causes loss of the metals. This
suggests that loss of catalytic activity in the presence of vardenafil is due to two factors: 1)
direct competition between vardenafil and cGMP for access to the catalytic site and 2)
vardenafil-induced loss of divalent cations from the catalytic site.
To study whether the inactive PDE5-vardenafil complex can regain the catalytic activity, the
PDE5A1 catalytic domain (residues 535–860) was mixed with 1.5 mM vardenafil for 4 h and
then passed through a Sephacryl S300 gel filtration column in a plain running buffer of 20 mM
Tris-HCl, pH 7.5, 50 mM NaCl, and 1 mM 2-mercaptoethanol without inhibitor vardenafil.
The specific activities of the native PDE5, the PDE5-vardenafil complex, and the fraction
eluted from the S300 column were measured at five repeats by using a method previously
described (Wang et al., 2006) and the assay buffer of 20 mM Tris-HCl, pH 7.5, 1.5 mM
dithiothreitol, 10 mM MgCl2, and 0.2 μM cGMP. They were 39.8 ± 0.6 nmol/min/mg for the
native PDE5 catalytic domain, 0.09 ± 0.02 for the protein in complex with 1.5 mM vardenafil,
and 2.0 ± 0.4 for the protein after passed the S300 column. Addition of 10 and 100 nM zinc to
the assay buffer increased the specific activity for the protein eluted from the S300 column by
approximately 2-fold (3.9 ± 1.1 and 4.4 ± 1.0 nmol/min/mg). The second time passing through
the S300 column did not further increase the activity. These experiments suggest that the
limited catalytic activity can be regained from the inactive PDE5-vardenafil complex by
passing the gel filtration column. The small percentage (10%) of activity recovery implies the
improper elution conditions or the trap of vardenafil in the closed active site.
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Different Configurations of Vardenafil and Sildenafil When Bound to PDE5A1
Vardenafil directly competes with cGMP for access to the catalytic pocket of PDE5A1, as does
sildenafil (Figs. 2 and 3). The binding involves three hydrogen bonds formed between O6 and
N1 of imidazotriazinone of vardenafil and Nε2 and Oε1 of Gln817 of PDE5A1 and between a
sulfonamide oxygen of vardenafil and the backbone nitrogen of Cys677 of PDE5A1. In
addition, two water molecules bind to O6 and N8 of the imidazotriazi-none. For hydrophobic
interactions, the propyl-imidazotriazinone of vardenafil stacks against Phe820 of PDE5A1 and
also contacts residues Tyr612, His613, Ile680, Leu765, Ala767, Ile768, Leu782, Phe786, and
Gln817. The ethoxy group orients to a hydrophobic pocket and interacts via van der Waals
forces with Ala779, Val782, Ile813, and Gln817. The phenyl group forms hydrophobic
interactions with Tyr676, Met816, Gln817, and Phe820. The ether oxygen of the ethoxyphenyl
group has a distance of 3.18 Å to the amide oxygen of the side chain of Gln817. This distance
is an unfavorable interaction because both oxygen atoms have no proton for formation of a
hydrogen bond and also because Gln817 is unlikely to switch its side-chain orientation because
of its pre-existing hydrogen bond with Gln775. The sulfonamide group (-SO2N) of vardenafil
contacts Tyr676, Cys677, and Ile680 of the H-loop, in addition to the stack against Phe820.
The ethylpiperazine group orients to the surface of the binding pocket and interacts with
Met816, Gly819, and Phe820.
Vardenafil binding to PDE5 shares a number of similarities with the binding characteristics of
sildenafil, including similar location of their ethoxyphenyl and imidazotriazinone/
pyrazolopyrimidinone groups, the same stacking against Phe820, and the hydrogen bonds with
Glu817 (Fig. 3). In addition, both inhibitors are buried in the catalytic pocket. The solvent-
accessible area of the bound vardenafil is only 8%, which compares well with 9.4% of the
bound sildenafil (Wang et al., 2006). However, the bound vardenafil shows molecular
configuration and interactions different from those of the bound sildenafil (Fig. 3). The key
difference is the orientation of the piperazine portion of two drugs. The ethylpiperazine of
vardenafil orients to the surface of the binding pocket and is extended to interact with residues
of Tyr676 to Ile680. In comparison, the methylpiperazine of sildenafil folds back to its
molecular entity and interacts with residues Asn662 to Ile665 of the H-loop, but not Tyr676-
Ile680, via van der Waals’ interactions.
Discussion
Vardenafil possesses a chemical structure very similar to sildenafil, but is 10- to 40-fold more
potent than sildenafil for PDE5 inhibition and a smaller clinically administered dosage for
treatment of erectile dysfunction (Saenz de Tejada et al., 2001; Corbin et al., 2004; Setter et
al., 2005; Supuran et al., 2006; Mehrotra et al., 2007). Thus, the structural basis for their
different biochemical and physiological properties has been a puzzle. The results of the early
studies on the crystal structures of PDE5A isolated catalytic domain in complex with sildenafil
and vardenafil showed the similar binding mode of these inhibitors but did not entirely agree
(Sung et al., 2003; Zhang et al., 2004). Vardenafil and sildenafil had the same extended
configuration in the structures by Sung et al. (2003), in contrast to the folded configuration of
both inhibitors in the report by Zhang et al. (2004) (Fig. 3). The different orientations of the
piperazine tails of the inhibitors seem to result from the rotation of the single C-S bond.
Although the energy barrier for the single bond rotation is minimal in theory, it is rare that the
same inhibitors adopt different conformations when bound to their receptors. Because the
PDE5A catalytic domain used by Sung et al. (2003) was basically inactive and the structure
reported by Zhang et al. (2004) contains a chimeric replacement of the PDE5A H-loop with
the PDE4D H-loop, the biologically relevant configurations of these inhibitors is in question.
The configuration of vardenafil in our structure is similar to that in the structure reported by
Sung et al. (2003), whereas our sildenafil configuration is similar to that reported by Zhang et
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al. (2004). Because our PDE5 protein is fully active and contains all native PDE5 residues, the
configuration difference between vardenafil and sildenafil is likely to be relevant to the
biological and physiological properties of these inhibitors.
Our previous studies have already shown that the H-loop of PDE5A is highly flexible and can
adopt different conformations and positional locations upon binding of the inhibitors (Wang
et al., 2006). This study adds significant new structural information pertaining to the
interactions between PDE5 and vardenafil. Although it is not clear whether the individual
conformation of the H-loop can be exploited for design of new PDE5 inhibitors, the flexibility
of the H-loop is likely to be an important allosteric mechanism that affects substrate and
inhibitor binding. The isolated PDE5A1 catalytic domain showed similar binding affinity with
vardenafil and sildenafil, and the vardenafil affinity is significantly boosted by the involvement
of GAF-B of PDE5A1 regulatory domain (Blount et al., 2006). This implies that the unique
features associated with the interaction of each of these inhibitors with the PDE5 catalytic
domain are likely to play a major role in determining the influence of the regulatory domain
on inhibitor affinity. A full understanding of the molecular effects of these inhibitors will
require further structural study within the context of the PDE5 holoenzyme.
It is interesting to note that the PDE4-selective inhibitor rolipram caused relocalization of the
full-length PDE4A4 and was suggested to trigger a conformational change on a loop interacting
with Mg2+ (Terry et al., 2003). Besides, the binding of cAMP to the GAF domain of
trypanosome PDEB1 (Laxman et al., 2005) and cGMP to the GAF domain of human PDE5
(Zoraghi et al., 2005) induced the allosteric conformational changes of the enzymes. These
observations, together with the structural study done here, suggest that conformational changes
promoted by the binding of inhibitors and substrates in the certain PDE families are essential
for the regulations such as phosphorylation of PDE4 and cGMP/cAMP binding to GAF
domains of PDEs. The H-loop of PDE5 likely serves as a key mediator of the allosteric
regulation of enzymatic activity.
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ABBREVIATIONS
PDE cyclic nucleotide phosphodiesterase
IBMX 3-isobutyl-1-methylxanthine
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Chemical structures of PDE5 inhibitors. Sildenafil, vardenafil, tadalafil, and udenafil are drugs
for treatment of erectile dys-function. IBMX is a nonselective inhibitor of most class I PDE
families.
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PDE5 structures. A, structural superimposition between the complexes of PDE5-vardenafil
and PDE5-sildenafil. The cyan ribbons represent their comparable structures. The H- and M-
loops of PDE5-sildenafil are shown in gold. The H-loop in the PDE5-vardenafil structure is
shown in green. The dotted lines represent the disordered residues in the H- and M-loops. B,
interactions between vardenafil and PDE5A1 residues. C, the electron density for vardenafil.
The (Fo-Fc) map was calculated from the structure with omission of vardenafil and is contoured
at 3 sigmas. D, the superimposition of the metal-binding residues between PDE5A1-vardenafil
(green) and PDE5A1-sildenafil (gold). The zinc and magnesium ions were drawn from the
sildenafil complex, but were absent in the PDE5A1-vardenafil complex.
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Superimposition of PDE5A1-vardenafil (green and cyan ribbons and green bonds) over
PDE5A1-sildenafil (golden ribbons and blue bonds). As a consequence of the different
positions of both H-and M-loops between the PDE5A1 complexes of vardenafil and sildenafil,
Tyr676, Cys677, and Ile680 interact with vardenafil, whereas Asn662, Ser663, and Leu804
interact with sildenafil. B, superposition of vardenafil (green) over sildenafil reported early by
our group (Wang et al., 2006). C, superposition of sildenafils reported by us (Wang et al.,
2006) (green), by Zhang et al. (2004) (gold), and by Sung et al., (2003) (cyan). D, superposition
of vardenafils from the same three groups.
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TABLE 1
Statistics on diffraction data and structure refinement
Data Collection
    Space group P212121
    Unit cell (a, b, c, Å) 68.9, 87.8, 138.5
    Resolution (Å) 2.07
    Unique reflections 47,379
    -Fold of redundancy 12.9
    Completeness (%) 91.1 (48.2)a
    Average I/σ 12.0 (3.6)a
    Rmerge 0.051 (0.28)a
Structure Refinement
    R factor 0.216
    Rfree 0.248 (10%)b
    Resolution (Å) 30–2.07
    Reflections 45,502
    RMS deviation for
        Bond (Å) 0.006
        Angle 1.1°
Average B-factor (Å2)
    Protein 43.4 (4720)c
    Vardenafil 35.2 (68)c
    Waters 40.3 (183)c
a
The numbers in parentheses are for the highest resolution shell.
b
The percentage of reflections omitted for calculation of Rfree.
c
The number of atoms in the crystallographic asymmetric unit.
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